Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21393582 | 0.76 | KDM4E (0.49) | TRPA1POLBHTTHPGD | |
| SCHEMBL21393588 | 0.73 | ALDH1A1 (0.41) | TRPA1POLBHTTHPGD | |
| SCHEMBL22477732 | 0.71 | ALDH1A1 (0.38) | TRPA1POLBHTTHPGD | |
| SCHEMBL7809883 | 0.71 | ADORA2A (0.47) | TLR8MEN1MAPTKMT2A | |
| SCHEMBL22477705 | 0.71 | ALDH1A1 (0.39) | TRPA1POLB | |
| SCHEMBL21363587 | 0.71 | ALDH1A1 (0.39) | TRPA1POLB | |
| SCHEMBL9059983 | 0.68 | PDE4A (0.55) | TLR8TRPA1 | |
| SCHEMBL16972522 | 0.66 | MAPT (0.44) | TRPA1POLBMAPTPKMHPGD | |
| SCHEMBL16972532 | 0.66 | ADORA2B (0.47) | AGTR1AGTR2 | |
| SCHEMBL1170110 | 0.66 | TLR8 (1.00) | TLR8CXCR4POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | TLR8 1901/4885TRPA1 2803/4885PNP 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.